MRVI - Maravai LifeSciences Holdings, Inc.
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI - Get Free Report) has received an average recommendation of "Hold" from the five ratings firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company.
SAN DIEGO--(BUSINESS WIRE)--TriLink BioTechnologies, LLC (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, today announced it has been granted a new patent from the China National Intellectual Property Administration (CNIPA), Patent number ZL202511246658.5., named "Compositions and Methods for Synthesizing 5'-Capped RNAs." The patent marks TriLink's second granted CleanCap® patent in China within a matter of months, and expands.
Maravai (MRVI) is evolving into an integrated supplier for the in vitro transcription (IVT) RNA workflow, embedding products across the customer lifecycle. Q2 2026 marked a profitability inflection, with gross margins rising to 40.1% and Adjusted EBITDA turning positive, reflecting successful cost realignment and segment-level improvement. TriLink's integrated GMP enzyme facility and ModTail technology strengthen customer stickiness, while Cygnus provides recurring, high-margin biologics safety earnings.
Dimensional Fund Advisors LP boosted its holdings in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) by 64.8% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,418,597 shares of the company's stock after buying an additional 558,050 shares during the
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI - Get Free Report) shares gapped down before the market opened on Friday. The stock had previously closed at $6.25, but opened at $5.60. Maravai LifeSciences shares last traded at $5.6880, with a volume of 683,238 shares. Key Headlines Impacting Maravai LifeSciences Here are the key news stories impacting
Maravai LifeSciences Holdings, Inc. (MRVI) Q2 2026 Earnings Call Transcript
Maravai LifeSciences (NASDAQ: MRVI) reported second-quarter 2026 revenue growth and a sharp improvement in adjusted profitability, while maintaining its full-year revenue outlook and raising its adjusted EBITDA forecast. Revenue for the quarter was $51.4 million, up 9% from the prior-year period. CEO Bernd Brust said the performance extended momentum established in the first quarter, led by
Maravai LifeSciences NASDAQ: MRVI reported second-quarter 2026 revenue growth and a sharp improvement in adjusted profitability, while maintaining its full-year revenue outlook and raising its adjusted EBITDA forecast.
Maravai LifeSciences Holdings, Inc. (MRVI) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.08 per share a year ago.
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the second quarter ended June 30, 2026, together with other business updates. Key Financial Results: Quarterly revenue of $51.4 million, Net loss of $(21.6) million, and Adjusted EBITDA of $8.7 million; Full year 2026 Adjusted EBITDA guidance raised to $33 million to $35 milli.
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its second quarter financial and operating results after the market close on Thursday, August 6, 2026, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial 1-800-579-2543 or 1-785-424-1789 and reference Maravai.
SAN DIEGO--(BUSINESS WIRE)--TriLink BioTechnologies, LLC (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has been granted a new patent from the China National Intellectual Property Administration (CNIPA), Patent number ZL 2025 1 1246578.X, covering methods of synthesizing RNA molecules. The new patent covers TriLink's full suite of CleanCap® capping analogs, including its latest M6 analog. CleanCap technology is a critical com.
TriLink, part of Maravai LifeSciences (NASDAQ: MRVI), today announced the opening of its GMP enzyme manufacturing facility in Jupiter, Florida, designed to h
JUPITER, Fla.--(BUSINESS WIRE)--TriLink, part of Maravai LifeSciences® (NASDAQ: MRVI), today announced the opening of its GMP enzyme manufacturing facility in Jupiter, Florida, designed to help RNA therapeutic developers simplify sourcing and scale production more efficiently. The facility supports a coordinated supply of key RNA manufacturing and IVT workflow materials from early research through commercial production. The launch addresses a long-standing pain point for RNA therapeutics develo.
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that certain of its subsidiaries have entered into a new credit agreement providing the Company with a $150 million term loan facility and a $30 million revolving credit facility. Borrowings under the new term loan facility, together with approximately $98.5 million of cash on hand, were used to prepay outs.
Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that the Company will participate in the following investor conference in June. On June 4, 2026, at 12:50 p.m. Eastern Time, Raj Asarpota, Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York City, NY. A live webcast of the fireside chat will be on th.
Maravai LifeSciences Holdings, Inc. is upgraded to Buy, driven by operational restructuring, improved guidance, and sector recovery. MRVI raised 2026 revenue guidance to $205–$215M and adjusted EBITDA to $30–$32M, reflecting robust Q1 results and cost savings. TriLink segment showed 15% YoY growth; restructuring actions are delivering over $65M in annual EBITDA savings.
Maravai LifeSciences Holdings, Inc. (MRVI) Q1 2026 Earnings Call Transcript
Maravai LifeSciences NASDAQ: MRVI reported first-quarter fiscal 2026 results that management said marked a “strong start to 2026,” driven by growth at its TriLink segment, steady contribution from Cygnus, and the impact of restructuring actions taken last year.